Prescribers must be certified in the TEGSEDI REMS Program to be able to prescribe TEGSEDI for adult patients with polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR). Because of the safety profile of TEGSEDI, patients treated with TEGSEDI should have lab monitoring prior to initiating therapy and ongoing monitoring during treatment as described in the Prescribing Information.
To become certified in the program, prescribers must complete the following steps:
REVIEW the TEGSEDI Prescribing Information
REVIEW the Prescriber Training and REMS Program Overview
COMPLETE AND SUBMIT the following online:
VIA FAX at 855-483-4736
RECEIVE notification of successful enrollment and username and password to log in to the TEGSEDI REMS Program and view your enrolled patients